S. Louise Phanstiel

Chair of the Board

S. Louise Phanstiel, Chair of the Board of Directors, has been a director of Myriad since September 2009, held several executive positions at Anthem, Inc., formerly WellPoint, Inc. from 1996 to 2007.  She was President, Specialty Products which included behavioral health services; Senior Vice President, Chief of Staff and Corporate Planning in the Office of the Chairman; and Chief Accounting Officer, Controller and Chief Financial Officer for all WellPoint, Inc. subsidiaries.  Previously, Ms. Phanstiel was a partner at the international services firm PricewaterhouseCoopers, LLP, formerly Coopers & Lybrand, LLP where she specialized in insurance.  Ms. Phanstiel’s life science experience includes having previously served on the Board of Directors and Chair of the Audit Committees at publicly traded companies, Inveresk Research Group, Inc. and Verastem, Inc.

Lawrence C. Best


Lawrence C. Best, a Director of the company since September 2009, joined Boston Scientific Corporation in 1992 and served for 15 years as the Executive Vice President-Finance & Administration and Chief Financial Officer. Prior to joining Boston Scientific, Mr. Best was a partner in the accounting firm of Ernst & Young, where he specialized in serving multinational companies in the high technology and life sciences fields. He served a two-year fellowship at the SEC from 1979 to 1981 and a one-year term as a White House-appointed Presidential Exchange Executive in Washington, D.C. He currently serves on the Board of Directors of Haemonetics Corp. and is a founding director of the President’s Council at Massachusetts General Hospital. Mr. Best received a B.B.A. degree from Kent State University.

Heiner Dreismann Ph.D.


Heiner Dreismann, Ph.D., joined the company in June 2010. Dr. Dreismann had a successful career at the Roche Group from 1985 to 2006 where he held several senior positions, including President and CEO of Roche Molecular Systems, Head of Global Business Development for Roche Diagnostics and Member of Roche’s Global Diagnostic Executive Committee. Dr. Dreismann currently serves on the boards of several public and private health care companies. He earned a master of science degree in biology and his doctor of philosophy degree in microbiology/molecular biology (summa cum laude) from Westfaelische Wilhelms University (The University of Münster) in Germany.

Walter Gilbert Ph.D.

Director, Vice Chairman of the Board

Walter Gilbert, Ph.D., Vice Chairman of the Board of Directors, joined the company as a founding scientist in March 1992. Dr. Gilbert won the Nobel Prize in Chemistry in 1980 for his contributions to the development of DNA sequencing technology. He was a founder of Biogen, Inc. and its Chairman of the Board and Chief Executive Officer from 1981 to 1985, as well as the Carl M. Loeb University Professor at Harvard University. Presently, he is a general partner of BioVentures Investors.

John T. Henderson M.D.


John T. Henderson, M.D. joined the company in May 2004, and served as a chair of the Board of Directors from April 2005 to March 2020. He previously was with Pfizer for over 25 years, most recently as a vice president in the Pfizer Pharmaceuticals Group. He also held vice president level positions with Pfizer in research and development in Europe and Japan, and was vice president, Medical for Europe, U.S. and International Pharmaceuticals group. Dr. Henderson has a bachelor’s and medical degree from the University of Edinburgh and is a fellow of the Royal College of Physicians.

Dennis Langer M.D, J.D.


Dennis Langer, M.D., J.D. is a Director of the company as of May 2004. He was previously Senior Vice President in Research and Development at GlaxoSmithKline and has a broad base of experience in innovative R&D companies such as Eli Lilly, Abbott and GD Searle. He is also a Clinical Professor at the Department of Psychiatry, Georgetown University School of Medicine. Dr. Langer has earned a J.D. (cum laude) from Harvard Law School, an M.D. from Georgetown University School of Medicine, and a B.A. in Biology from Columbia University.

Lee N. Newcomer M.D.


Lee N. Newcomer, M.D., board-certified medical oncologist, joined the company in September 2019. Most recently, he was Senior Vice President of Oncology and Genetics for UnitedHealthcare. Previously, he served as Chief Medical Officer and Senior Vice President of Health Policy and Strategy at UnitedHealth Group, and Chief Medical Officer at Vivius, Inc. Dr. Newcomer earned a M.D. from University of Nebraska College of Medicine, a M.H.A from University of Wisconsin-Madison and a B.A. from Nebraska Wesleyan.

Colleen F. Reitan


Colleen F. Reitan joined the company in September 2019. Most recently, she served as President of Plan Operations for Healthcare Service Corporation (HCSC). Prior to that, she held several roles, including serving as the Executive Vice President and Chief Operating Officer of HCSC and President and Chief Operating Officer of Blue Cross & Blue Shield of Minnesota. She previously served on boards at Availity LLC, MEDecision, Inc. and Prime Therapeutics LLC. Reitan has a M.H.A. from the University of Minnesota and a B.A. in Urban Studies and Economics from Minnesota State University.

Daniel M. Skovronsky


Daniel M. Skovronsky, M.D., Ph.D., joined the company as a Director in July 2020. Currently, he serves as Chief Science Officer and President of Lilly Research Laboratories at Eli Lilly and Company. Previously, he was Chief Executive Officer of Avid Radiopharmaceuticals Inc., a company he founded in 2004. Dr. Skovronsky earned his M.D. from the Perelman School of Medicine, University of Pennsylvania, his Ph.D. in neuroscience from University of Pennsylvania and a B.S. in molecular biophysics and biochemistry from Yale University.

Daniel K. Spiegelman


Daniel K. Spiegelman has been a Director of the company since May 2020. Most recently, he served as Executive Vice President and Chief Financial Officer at BioMarin Pharmaceuticals, Inc. Prior to that, he held several roles, including Senior Vice President and Chief Financial Officer of CV Therapeutics and Treasurer at Genentech, Inc. He is currently a member of the board of directors at Tizona Therapeutics, Inc., a private pharmaceutical company. Mr. Spiegelman received a B.A. degree from Stanford University and a M.B.A. from the Stanford Graduate School of Business.